查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1808353

生物技术与製药服务外包市场按服务类型、外包类型、公司规模、治疗领域和服务供应商类型划分 - 全球预测，2025-2030 年

Biotechnology & Pharmaceutical Services Outsourcing Market by Service Type, Mode of Outsourcing, Company Size, Therapeutic Area, Service Provider Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

生技和製药服务外包市场预计到 2024 年将达到 554.2 亿美元，2025 年将达到 585.4 亿美元，到 2030 年将达到 773.8 亿美元，复合年增长率为 5.71%。

主要市场统计数据
基准年2024年 554.2亿美元
预计2025年 585.4亿美元
预测年份 2030 773.8亿美元
复合年增长率（%） 5.71%

探索塑造当今生物技术和製药外包产业的策略基础和关键驱动因素

生物技术和製药服务外包行业正处于关键的十字路口，受治疗创新的不断发展和成本压力的不断增加的驱动。细胞和基因疗法的快速发展，加上日益复杂的临床和监管要求，正在推动对外部专业知识的需求。同时，企业正面临严格的审查，以加快上市时间、维持品质标准并优化资本配置。

检验正在重新定义医药外包领域服务交付的重大技术进步和营运转型

近年来，随着先进的分析工具和自动化平台重新定义了营运预期，外包格局发生了重大转变。人工智慧驱动的研究设计和机器学习主导的数据分析正在支撑决策支援系统，并加速化合物选择和患者招募策略。同时，云端基础的协作入口网站已成为即时资料交换的关键，有助于提高地理位置分散的团队之间的透明度和合规性。

揭示2025年美国关税对生物技术和製药外包的更广泛的经济和贸易政策影响

美国将于2025年实施新的关税制度，这将在从海外合作伙伴采购实验室用品、原料药和设备时引入复杂的成本和合规考量。依赖全球供应链的製造商和临床研究机构正面临不断上涨的关税，这促使他们重新评估其供应商组合和物流网络。为了应对这些不利因素，许多相关人员正在探索近岸外包方案，并与国内受託製造厂商合作，以规避关税的影响。

探索细分洞察，揭示服务类型、外包模式、公司规模、治疗领域和提供者类型将如何影响产业成长

对市场区隔进行严格的检验，可以发现各种服务类型（从临床试验阶段到复杂的监管策略支援）的需求驱动因素存在细微差别。 I期至IV期临床试验服务持续受到广泛关注，因为申办方寻求端到端患者招募和场地管理方面的专业知识；而咨询服务（包括併购咨询和打入市场策略）也越来越多地被用于应对不断变化的报销制度。

分析美洲、欧洲、中东和非洲地区以及亚太地区外包产业的独特监管环境和创新能力

不同地区拥有不同的创新生态系统和法律规范都会影响外包策略。在美洲，生物技术中心和顶级临床机构的集中推动了对全方位服务解决方案的需求，而积极的贸易政策和奖励则推动了国内製造业的扩张。不断变化的报销模式以及对以患者为中心的临床试验的关注，正在推动分散式临床服务的成长。

评估塑造生物製药行业的领先委外研发机构和咨询公司的竞争方式、伙伴关係和成长路径

领先的合约研究机构正透过策略联盟、地理扩张和端到端平台整合来脱颖而出。一些主要企业正在寻求与专业的生物技术公司建立合资企业，共同开发细胞疗法生产和高级分析领域的利基能力。这些联盟增强了他们的服务组合，并加速了最尖端科技的获取。

生物製药外包领导者提供可行的策略建议，以优化服务交付创新和营运弹性

产业领导者应优先投资数位平台，以促进全球企划团队之间的无缝协作，并加速即时数据视觉化。采用先进的分析技术和人工智慧主导的决策支援工具，不仅可以简化研究设计和病患招募，还能增强监管链中的风险管理和品质监督。

结合主要专家访谈、全面的二次研究和数据三角测量方法的严谨多模态调查方法的详细信息

研究采用全面的多模态方法，首先广泛查阅同行评审出版物、行业白皮书和监管文件，以建立坚实的二手资料基础。此外，研究还整合了政府资料库和专业产业报告的关键见解，以全面检验市场趋势和政策发展。

全面检视关键趋势：医药服务外包相关人员的策略意义与未来前景

在技​​术创新、贸易政策演变和客户偏好变化的推动下，生物技术和製药服务外包生态系统正在迅速成熟。策略合作、数位转型和地理扩张正成为企业成长和韧性的关键槓桿。为了满足这些需求，企业必须在专业知识需求与一体化服务模式所带来的效率之间取得平衡。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 快速采用人工智慧平台加速合约研究服务中的药物发现
  • 个人化医疗需求的不断增长推动了专业外包解决方案的扩张
  • 细胞和基因治疗外包的快速成长需要扩大专业製造能力
  • 在製药外包业务中融入永续性和绿色化学实践
  • 真实世界证据和数据分析在製定外包临床试验策略中的作用日益增强
  • CDMO之间的整合推动了生物製造服务领域的策略伙伴关係和产能优化
  • 影响临床试验和药物核准全球外包的监管协调倡议
  • 医药服务外包合约中更重视风险缓解和供应链弹性
  • 数位化病人参与工具的出现改变了临床试验的现场管理和远端监控
  • 实施连续生产流程，加速外包合约设施的生物製药生产

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

8. 生技和製药服务外包市场（依服务类型）

  • 临床试验服务
    • 第一阶段
    • 第二阶段
    • 第三阶段
    • 第四阶段
  • 咨询服务
    • 併购咨询
    • 市场进入及报销咨询
    • 投资组合管理
    • 策略咨询
  • 製造服务
    • API 製造
    • 合约开发与製造组织 (CDMO) 服务
    • 灌装和精加工服务
    • 配方开发
    • 包装和标籤
    • 扩大规模和技术转移
  • 药物警戒服务
  • 临床前服务
    • 动物实验
    • 生物分析测试
    • DMPK研究
    • 药理学研究
    • 毒性测试
  • 品管服务
  • 监管服务
    • 代理通讯及代表
    • 文件准备
    • 标籤和包装合规性
    • 药物警戒和安全监测
    • 监理策略和备案
  • 研发服务
    • 检测方法开发
    • 生物标记发现
    • 线索识别和优化
    • 目标检验

9. 生技和製药服务外包市场（依外包类型）

  • 全方位服务外包
  • 功能服务供应商（FSP）模型
  • 战术性/企划为基础的外包

第 10 章：生物技术和製药服务外包市场（按公司规模）

  • 大公司
  • 小型企业

第 11 章。生物技术和製药服务外包市场（按治疗领域）

  • 心血管系统
  • 皮肤科
  • 胃肠病学
  • 免疫学
  • 感染疾病
  • 代谢紊乱
  • 神经病学
  • 肿瘤学
  • 小儿科
  • 罕见疾病
  • 呼吸系统

第 12 章：生物技术和製药服务外包市场（按服务供应商类型）

  • 顾问公司
  • 合约开发和製造组织（CDMO）
  • 契约製造组织（CMO）
  • 合约研究组织（CRO）
  • 资料管理和 IT服务供应商
  • 监管事务公司

13.美国生技与製药服务外包市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14.欧洲、中东和非洲生物技术和製药服务外包市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

15. 亚太生物技术和製药服务外包市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十六章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • AmerisourceBergen Corporation
    • Catalent, Inc.
    • CEVA Logistics AG
    • Charles River Laboratories, Inc.
    • Concept Heidelberg GmbH
    • Curia Global, Inc.
    • Dalton Pharma Services by Seikagaku Corporation
    • DHL International GmbH
    • Eurofins Scientific（Ireland）Limited
    • Evotec SE
    • GenScript Biotech Corporation
    • Icon PLC
    • IQVIA HOLDINGS, INC.
    • Laboratory Corporation of America Holdings
    • Lachman Consultant Services, Inc.
    • McKesson Corporation by Aurelius Group
    • Medpace Holdings, Inc.
    • Parexel International Corporation
    • Syneos Health, Inc.
    • Thermo Fisher Scientific Inc.
    • WuXi AppTec Co., Ltd.

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

Product Code: MRR-3A2E844FE146

The Biotechnology & Pharmaceutical Services Outsourcing Market was valued at USD 55.42 billion in 2024 and is projected to grow to USD 58.54 billion in 2025, with a CAGR of 5.71%, reaching USD 77.38 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 55.42 billion
Estimated Year [2025] USD 58.54 billion
Forecast Year [2030] USD 77.38 billion
CAGR (%) 5.71%

Discovering the Strategic Foundations and Critical Drivers Shaping the Biotechnology and Pharmaceutical Outsourcing Industry Today

The biotechnology and pharmaceutical services outsourcing sector stands at a pivotal juncture, driven by evolving therapeutic innovations and mounting cost pressures. Rapid advancements in cell and gene therapies, coupled with the increasing complexity of clinical and regulatory requirements, have expanded the demand for specialized external expertise. Meanwhile, organizations are under relentless scrutiny to accelerate time to market, maintain quality standards and optimize capital deployment.

Within this dynamic environment, outsourcing partners play an instrumental role in augmenting in-house capabilities and mitigating operational risks. An array of service models now spans from full-service contract research organizations to tactical project-based support, allowing companies to tailor collaborations according to strategic imperatives. In parallel, digital transformation initiatives are reshaping traditional workflows, driving deeper integration between sponsors and service providers.

As industry stakeholders adapt to these shifts, understanding the strategic foundations and key drivers becomes essential for informed decision making. This introduction sets the stage by outlining core market catalysts such as regulatory complexity, technological innovation and economic considerations. By contextualizing these forces, readers will gain clarity on the factors shaping service demand and partnership models, preparing them to navigate an increasingly competitive and interconnected outsourcing landscape.

Examining the Dramatic Technological Advancements and Operational Transformations Redefining Service Delivery in the Pharmaceutical Outsourcing Landscape

In recent years, the outsourcing landscape has undergone profound transformation as advanced analytical tools and automation platforms have redefined operational expectations. Artificial intelligence-powered trial designs and machine learning-driven data analytics now underpin decision support systems, accelerating compound selection and patient recruitment strategies. Concurrently, cloud-based collaboration portals have become integral for real-time data exchange, fostering enhanced transparency and compliance across geographically dispersed teams.

These technological breakthroughs coincided with a shift toward more hybridized service offerings. Traditional full-service models are increasingly complemented by specialized functional service provider arrangements, enabling clients to maintain direct oversight of critical study components while outsourcing noncore functions. As a result, service providers are expanding niche capabilities-such as advanced biomarker discovery or adaptive trial management-to differentiate their value proposition and forge deeper partnerships.

Moreover, sustainability considerations and social responsibility initiatives are influencing provider selection. Clients now prioritize partners with robust environmental, social and governance frameworks, viewing these commitments as indicators of operational resilience and ethical stewardship. As the industry evolves, service organizations that integrate cutting-edge technologies with flexible operating models and strong ESG practices will be best positioned to lead the next wave of outsourcing innovation.

Unpacking the Broad Economic and Trade Policy Effects of the United States Tariffs on Biotechnology and Pharma Outsourcing in 2025

The imposition of new tariff regimes by the United States in 2025 has introduced a complex layer of cost and compliance considerations for sourcing laboratory supplies, active pharmaceutical ingredients and equipment from overseas partners. Manufacturers and clinical research organizations reliant on global supply chains have encountered elevated duties, prompting a reassessment of supplier portfolios and logistics networks. To manage these headwinds, many stakeholders are exploring near-shoring options and forging partnerships with domestic contract development and manufacturing organizations to circumvent tariff exposures.

At the same time, increased duties on specialized reagents and analytical instruments have led to pricing pressures across preclinical and clinical development activities. Service providers are responding by negotiating volume discounts, implementing consolidated shipping strategies and adopting lean inventory practices. These adjustments have delivered near-term cost relief but also introduced complexity into demand forecasting and capacity planning.

Strategically, the tariff landscape has incentivized dual-sourcing frameworks to mitigate single-source vulnerabilities. By diversifying procurement channels and investing in regional manufacturing footprints, companies can better manage financial risks and maintain continuity. In this evolving trade policy environment, proactive supply chain optimization and collaborative vendor ecosystems are emerging as critical enablers for sustaining efficient outsourcing operations.

Uncovering Segmentation Insights That Illuminate How Service Types Outsourcing Models Company Sizes Therapeutic Areas and Provider Types Shape Industry Growth

A rigorous examination of market segmentation uncovers nuanced demand drivers across a spectrum of service types ranging from clinical trial phases to complex regulatory strategy support. Clinical trial services spanning phases I through IV continue to capture significant attention as sponsors seek end-to-end patient recruitment and site management expertise, while consulting services encompassing M&A advisory and market access strategy are increasingly leveraged to navigate changing reimbursement landscapes.

Within manufacturing, specialized contract development and manufacturing organizations offering formulation development and scale-up capabilities are gaining traction, especially for novel modalities. Preclinical suppliers delivering bioanalytical testing and toxicology assessments play a critical role in de-risking early-stage assets, while pharmacovigilance and quality management services ensure rigorous safety monitoring throughout the product lifecycle. Moreover, research and development firms focusing on assay development, biomarker discovery and target validation provide indispensable insights that refine lead optimization and accelerate translational research.

The mode of outsourcing further differentiates strategic alignment: full-service partnerships deliver integrated program management, whereas functional service provider models and project-based engagements offer targeted flexibility. Additionally, the interplay between large enterprises and small to medium-sized biotechnology firms shapes procurement preferences, with larger sponsors often favoring comprehensive end-to-end solutions while emerging companies selectively outsource high-value research tasks. Finally, therapeutic area specialization and provider type-ranging from contract research to data management and regulatory affairs firms-reflect diverse competency needs and drive differential growth trajectories across the industry.

Analyzing the Unique Regional Drivers Regulatory Landscapes and Innovation Capacities Shaping the Americas EMEA and AsiaPacific Outsourcing Sectors

Regional dynamics reveal distinct innovation ecosystems and regulatory frameworks that influence outsourcing strategies. In the Americas, a robust concentration of biotech hubs and top-tier clinical sites drives demand for full-service solutions, while proactive trade policies and incentives support domestic manufacturing expansion. Shifting reimbursement models and an emphasis on patient-centric trials further spur growth in decentralized clinical service offerings.

Across Europe, the Middle East and Africa, harmonized regulatory initiatives such as the EU Clinical Trials Regulation are fostering greater cross-border collaboration and standardization in safety reporting. This regulatory convergence, combined with established contract research infrastructure, has elevated the region's appeal for midstage and late-stage clinical programs. At the same time, emerging markets within the Middle East and Africa are attracting investments in site development and pharmacovigilance capabilities, underpinned by government-sponsored research partnerships.

In the AsiaPacific corridor, rapid capacity expansion in contract development and manufacturing is reshaping global supply chain architectures. Nations across the region are investing heavily in biotech clusters, incentivizing API production and advanced fill-finish platforms. The integration of digital health initiatives and supportive regulatory frameworks accelerates clinical trial innovation, making AsiaPacific an increasingly strategic destination for cost-efficient, high-quality outsourced services.

Evaluating the Competitive Approaches Partnerships and Growth Paths of Major Contract Research Manufacturing and Consulting Organizations Shaping Biopharma

Leading contract research organizations are differentiating through strategic alliances, geographic footprint expansion and end-to-end platform integrations. Several top players have pursued joint ventures with specialized biotech firms to co-develop niche capabilities in cell therapy manufacturing and advanced analytics. These partnerships enhance service portfolios and accelerate access to cutting-edge technologies.

Similarly, leading CDMOs are investing in modular facility designs that support agile production scale-up, addressing the growing demand for personalized medicine manufacturing. To strengthen downstream capabilities, some providers have acquired packaging and labeling specialists, thereby streamlining tech transfer processes and minimizing regulatory hurdles. Contract manufacturing organizations also continue to refine their quality and compliance frameworks to meet the stringent standards required for biologics and high-potency compounds.

Consulting firms and regulatory affairs specialists are forging closer collaborations with industry associations and regulatory agencies to influence policy dialogues and expedite dossier approvals. Data management and IT service providers, in turn, are embedding robust cybersecurity and AI-driven analytics into trial management systems to optimize data integrity and accelerate decision cycles. Collectively, these competitive strategies underscore the imperative for integrated service offerings and continuous innovation to maintain leadership positions in the biopharma outsourcing arena.

Providing Actionable Strategic Recommendations for Biopharma Outsourcing Leaders to Optimize Service Delivery Innovation and Operational Resilience

Industry leaders should prioritize investments in digital platforms that facilitate seamless collaboration across global project teams and accelerate real-time data visibility. Implementing advanced analytics and AI-driven decision support tools will not only streamline trial design and patient recruitment but also enhance risk management in chain-of-custody and quality oversight.

Furthermore, building resilient supply chains through diversified sourcing and near-shoring strategies can mitigate tariff-induced cost fluctuations and regulatory uncertainties. Organizations should cultivate strategic alliances with regional manufacturers and logistics partners to bolster capacity flexibility and accelerate response times during demand surges.

In parallel, fostering deep specialized expertise within niche therapeutic and technical domains can drive competitive differentiation. By aligning service offerings with emerging modalities such as cell and gene therapy, companies can capture higher-value contracts and strengthen long-term client relationships. Lastly, embedding robust environmental, social and governance principles into operational frameworks will not only address stakeholder expectations but also signal a commitment to sustainable and ethical practices, reinforcing brand integrity and stakeholder trust.

Detailing the Rigorous Multimodal Research Methodology Combining Primary Expert Interviews Comprehensive Secondary Research and Data Triangulation Approaches

This research employs a comprehensive multimodal approach beginning with an extensive review of peer-reviewed publications, industry white papers and regulatory filings to construct a solid secondary data foundation. Key insights from government databases and specialized trade reports were synthesized to validate overarching market trends and policy developments.

Primary research involved in-depth interviews with senior executives at leading service providers, global biopharma sponsors and regulatory experts to capture firsthand perspectives on operational challenges and emerging opportunities. Respondent feedback was systematically triangulated with quantitative and qualitative data points to ensure robust findings.

Data analysis combined thematic content evaluation with cross-functional benchmarking, enabling identification of service innovation patterns and competitive differentiation strategies. Finally, the integrated methodology was governed by strict data validation protocols, ensuring the reliability and reproducibility of insights while maintaining transparency of assumptions and limitations throughout the research lifecycle.

Concluding with Holistic Reflections Synthesizing Key Trends Strategic Implications and Future Perspectives for Pharmaceutical Service Outsourcing Stakeholders

The outsourcing ecosystem for biotechnology and pharmaceutical services is rapidly maturing, fueled by technological breakthroughs, evolving trade policies and shifting client preferences. Strategic collaborations, digital transformation and regional expansion have emerged as pivotal levers for growth and resilience. As companies adapt to these imperatives, they must balance the need for specialized expertise with the efficiencies offered by integrated service models.

Moreover, trade-driven cost pressures underscore the importance of supply chain diversification and near-shore manufacturing investments. Regulatory harmonization efforts across major markets continue to streamline clinical development pathways, yet demand for localized compliance expertise remains high. Segmentation insights reveal that no single operating model will suffice; rather, success hinges on the ability to tailor services to sponsor priorities-whether managing complex trial phases, navigating market access challenges or scaling novel therapy production.

Ultimately, industry participants that align strategic investments in technology, partnerships and ESG stewardship will be best positioned to capture emerging opportunities and mitigate systemic risks. The path forward is defined by agility, specialization and sustained innovation across the global outsourcing value chain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rapid adoption of artificial intelligence platforms enabling accelerated drug discovery in contract research services
  • 5.2. Growing demand for personalized medicine leading to expansion of specialized outsourcing solutions
  • 5.3. Surge in cell and gene therapy outsourcing requiring specialized manufacturing capacity expansions
  • 5.4. Integration of sustainability and green chemistry practices in pharmaceutical outsourcing operations
  • 5.5. Expanding role of real world evidence and data analytics in shaping outsourcing clinical trial strategies
  • 5.6. Consolidation among CDMOs driving strategic partnerships and capacity optimization in biomanufacturing services
  • 5.7. Regulatory harmonization initiatives influencing global outsourcing of clinical trials and drug approvals
  • 5.8. Increased focus on risk mitigation and supply chain resilience in pharmaceutical service outsourcing agreements
  • 5.9. Emergence of digital patient engagement tools transforming site management and remote monitoring in clinical trials
  • 5.10. Adoption of continuous manufacturing processes accelerating biologics production in outsourced contract facilities

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Biotechnology & Pharmaceutical Services Outsourcing Market, by Service Type

  • 8.1. Introduction
  • 8.2. Clinical Trial Services
    • 8.2.1. Phase I
    • 8.2.2. Phase II
    • 8.2.3. Phase III
    • 8.2.4. Phase IV
  • 8.3. Consulting Services
    • 8.3.1. M&A Advisory
    • 8.3.2. Market Access & Reimbursement Consulting
    • 8.3.3. Portfolio Management
    • 8.3.4. Strategic Consulting
  • 8.4. Manufacturing Services
    • 8.4.1. API Production
    • 8.4.2. Contract Development & Manufacturing Organization (CDMO) Services
    • 8.4.3. Fill-Finish Services
    • 8.4.4. Formulation Development
    • 8.4.5. Packaging & Labeling
    • 8.4.6. Scale-Up & Tech Transfer
  • 8.5. Pharmacovigilance Services
  • 8.6. Preclinical Services
    • 8.6.1. Animal Studies
    • 8.6.2. Bioanalytical Testing
    • 8.6.3. DMPK Studies
    • 8.6.4. Pharmacology Studies
    • 8.6.5. Toxicology Testing
  • 8.7. Quality Management Services
  • 8.8. Regulatory Affairs Services
    • 8.8.1. Agency Communication & Representation
    • 8.8.2. Dossier Preparation
    • 8.8.3. Labeling & Packaging Compliance
    • 8.8.4. Pharmacovigilance & Safety Monitoring
    • 8.8.5. Regulatory Strategy & Submissions
  • 8.9. Research & Development Services
    • 8.9.1. Assay Development
    • 8.9.2. Biomarker Discovery
    • 8.9.3. Lead Identification & Optimization
    • 8.9.4. Target Validation

9. Biotechnology & Pharmaceutical Services Outsourcing Market, by Mode of Outsourcing

  • 9.1. Introduction
  • 9.2. Full-Service Outsourcing
  • 9.3. Functional Service Provider (FSP) Model
  • 9.4. Tactical/Project-Based Outsourcing

10. Biotechnology & Pharmaceutical Services Outsourcing Market, by Company Size

  • 10.1. Introduction
  • 10.2. Large Enterprises
  • 10.3. Small & Medium Enterprises (SMEs)

11. Biotechnology & Pharmaceutical Services Outsourcing Market, by Therapeutic Area

  • 11.1. Introduction
  • 11.2. Cardiovascular
  • 11.3. Dermatology
  • 11.4. Gastroenterology
  • 11.5. Immunology
  • 11.6. Infectious Diseases
  • 11.7. Metabolic Disorders
  • 11.8. Neurology
  • 11.9. Oncology
  • 11.10. Pediatrics
  • 11.11. Rare Diseases
  • 11.12. Respiratory

12. Biotechnology & Pharmaceutical Services Outsourcing Market, by Service Provider Type

  • 12.1. Introduction
  • 12.2. Consulting Firms
  • 12.3. Contract Development & Manufacturing Organizations (CDMOs)
  • 12.4. Contract Manufacturing Organizations (CMOs)
  • 12.5. Contract Research Organizations (CROs)
  • 12.6. Data Management & IT Service Providers
  • 12.7. Regulatory Affairs Firms

13. Americas Biotechnology & Pharmaceutical Services Outsourcing Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Biotechnology & Pharmaceutical Services Outsourcing Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Biotechnology & Pharmaceutical Services Outsourcing Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AmerisourceBergen Corporation
    • 16.3.2. Catalent, Inc.
    • 16.3.3. CEVA Logistics AG
    • 16.3.4. Charles River Laboratories, Inc.
    • 16.3.5. Concept Heidelberg GmbH
    • 16.3.6. Curia Global, Inc.
    • 16.3.7. Dalton Pharma Services by Seikagaku Corporation
    • 16.3.8. DHL International GmbH
    • 16.3.9. Eurofins Scientific (Ireland) Limited
    • 16.3.10. Evotec SE
    • 16.3.11. GenScript Biotech Corporation
    • 16.3.12. Icon PLC
    • 16.3.13. IQVIA HOLDINGS, INC.
    • 16.3.14. Laboratory Corporation of America Holdings
    • 16.3.15. Lachman Consultant Services, Inc.
    • 16.3.16. McKesson Corporation by Aurelius Group
    • 16.3.17. Medpace Holdings, Inc.
    • 16.3.18. Parexel International Corporation
    • 16.3.19. Syneos Health, Inc.
    • 16.3.20. Thermo Fisher Scientific Inc.
    • 16.3.21. WuXi AppTec Co., Ltd.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET: RESEARCHAI
  • FIGURE 26. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET: RESEARCHSTATISTICS
  • FIGURE 27. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET: RESEARCHCONTACTS
  • FIGURE 28. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE IV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE IV, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY M&A ADVISORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY M&A ADVISORY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MARKET ACCESS & REIMBURSEMENT CONSULTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MARKET ACCESS & REIMBURSEMENT CONSULTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PORTFOLIO MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PORTFOLIO MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STRATEGIC CONSULTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STRATEGIC CONSULTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY API PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY API PRODUCTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION (CDMO) SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION (CDMO) SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FILL-FINISH SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FILL-FINISH SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SCALE-UP & TECH TRANSFER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SCALE-UP & TECH TRANSFER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ANIMAL STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ANIMAL STUDIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOANALYTICAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOANALYTICAL TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DMPK STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DMPK STUDIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOLOGY STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOLOGY STUDIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY QUALITY MANAGEMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY QUALITY MANAGEMENT SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AGENCY COMMUNICATION & REPRESENTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AGENCY COMMUNICATION & REPRESENTATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DOSSIER PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DOSSIER PREPARATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LABELING & PACKAGING COMPLIANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LABELING & PACKAGING COMPLIANCE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE & SAFETY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE & SAFETY MONITORING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY STRATEGY & SUBMISSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY STRATEGY & SUBMISSIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FULL-SERVICE OUTSOURCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FULL-SERVICE OUTSOURCING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TACTICAL/PROJECT-BASED OUTSOURCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TACTICAL/PROJECT-BASED OUTSOURCING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SMALL & MEDIUM ENTERPRISES (SMES), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SMALL & MEDIUM ENTERPRISES (SMES), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESPIRATORY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING FIRMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS (CMOS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS (CMOS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT & IT SERVICE PROVIDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT & IT SERVICE PROVIDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS FIRMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 149. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 151. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 153. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 155. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 157. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2025-2030 (USD MILLION)
  • TABLE 159. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
  • TABLE 161. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2025-2030 (USD MILLION)
  • TABLE 163. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2025-2030 (USD MILLION)
  • TABLE 165. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 167. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 177. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 178. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 179. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 181. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2025-2030 (USD MILLION)
  • TABLE 189. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 191. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2025-2030 (USD MILLION)
  • TABLE 193. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 194. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 195. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 197. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 198. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 199. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 200. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 201. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 202. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 203. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 204. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 205. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2018-2024 (USD MILLION)
  • TABLE 206. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2025-2030 (USD MILLION)
  • TABLE 207. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
  • TABLE 208. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
  • TABLE 209. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2018-2024 (USD MILLION)
  • TABLE 210. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2025-2030 (USD MILLION)
  • TABLE 211. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2018-2024 (USD MILLION)
  • TABLE 212. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2025-2030 (USD MILLION)
  • TABLE 213. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 214. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 215. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 219. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 220. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 221. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 222. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 223. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 224. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 225. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 226. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 227. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2018-2024 (USD MILLION)
  • TABLE 228. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2025-2030 (USD MILLION)
  • TABLE 229. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
  • TABLE 230. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
  • TABLE 231. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2025-2030 (USD MILLION)
  • TABLE 233. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2018-2024 (USD MILLION)
  • TABLE 234. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2025-2030 (USD MILLION)
  • TABLE 235. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 236. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 237. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. MEXICO BIOTECHNOLOGY & P